NASDAQ, ALKS - Alkermes Plc

The following business section contains forward-looking statements which  involve risks and uncertainties. Our actual results could differ materially from  those anticipated in these forward-looking statements as a result of certain  factors. See ?Risk Factors? and ?Management?s Discussion and Analysis of  Financial Condition and Results of Operations ? Forward-Looking Statements.?  General  Alkermes, Inc. (together with its subsidiaries, referred to as ?we?, ?us?,  ?our? or the ?Registrant?), a Pennsylvania corporation organized in 1987, is a  biotechnology company that develops products based on sophisticated drug  delivery technologies to enhance therapeutic outcomes in major diseases. We have  two commercial products. RISPERDAL? CONSTA?[(risperidone) long-acting injection]  is the first and only long-acting atypical antipsychotic medication approved for  use in schizophrenia and is marketed worldwide by Janssen-Cilag (?Janssen?), a  subsidiary of Johnson & Johnson.  ...

Sector:	Consumer Durables
Industry:	Major Pharmaceuticals
P/E Ratio:	13.7381
PEG Ratio:	N/A
EPS:	2.1
DivYield:	N/A
PtB:	3.1465
PtS:	10.5
EBITDA:	N/A
Shares:	164.9M
Market Cap:	4.403B
52wk range:	25.56 - 36.45

216.73.216.229
United States